2017
Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid
Castiglioni P, Hartley M, Rossi M, Prevel F, Desponds C, Utzschneider D, Eren R, Zangger H, Brunner L, Collin N, Zehn D, Kuhlmann F, Beverley S, Fasel N, Ronet C. Exacerbated Leishmaniasis Caused by a Viral Endosymbiont can be Prevented by Immunization with Its Viral Capsid. PLOS Neglected Tropical Diseases 2017, 11: e0005240. PMID: 28099431, PMCID: PMC5242429, DOI: 10.1371/journal.pntd.0005240.Peer-Reviewed Original ResearchConceptsSymptomatic relapseVaccinated miceVaccine strategiesPotent innate immunogenSimilar viral infectionsVirus-related complicationsT-cell transferSpecific T cellsPoor treatment responseLesional inflammationSerum transferT helperInitial treatmentC57BL/6 miceNaïve miceLeishmania infectionPreventive benefitsVaccine opportunitiesT cellsTreatment responseImmune responseViral infectionLesion sizeClinical effortsLeishmania guyanensis
2013
The therapeutic potential of immune cross‐talk in leishmaniasis
Hartley M, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross‐talk in leishmaniasis. Clinical Microbiology And Infection 2013, 19: 119-130. PMID: 23398405, DOI: 10.1111/1469-0691.12095.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntiprotozoal AgentsHumansImmunotherapyLeishmaniaLeishmaniasisMammalsRNA VirusesConceptsMetastatic leishmaniasisCutaneous leishmaniasisLeishmania parasitesSelf-healing lesionsProtozoan parasitic diseaseEffective antileishmanial drugsSpecies of LeishmaniaDestructive lesionsImmune homeostasisCurrent treatmentTherapeutic strategiesImmune pathwaysNew drug targetsTherapeutic potentialParasitic diseasesAntileishmanial drugsLeishmaniasisLesionsPrevalent formDiseaseDrug targetsRNA virusesTreatmentVariable effectsParasites